Ultime notizie per icad (NASDAQ:ICAD) Azioni

icad

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

icad Inc

Icade

<h3>Gainers</h3>
<ul>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) shares moved upwards by 33.8% to $6.69 during Thursday's pre-market session. The market value of their outstanding shares is at $59.4 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares moved upwards by 18.3% to $0.39. The company's market cap stands at $2.4 million. As per the press release, Q3 earnings came out today. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 16.98% to $0.39. The company's market cap stands at $2.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock increased by 16.23% to $3.58. The company's market cap stands at $126.2 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 13.01% to $1.12. The company's market cap stands at $7.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares increased by 11.96% to $11.88. The company's market cap stands at $670.3 million. The company's, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares fell 52.4% to $5.08 during Thursday's pre-market session. The company's market cap stands at $98.1 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock fell 23.08% to $1.8. The company's market cap stands at $47.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 22.77% to $4.75. The company's market cap stands at $87.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares fell 19.79% to $2.21. The company's market cap stands at $81.3 million. The company's, Q3 earnings came out today. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares decreased by 18.92% to $42.0. The company's market cap stands at $1.4 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares decreased by 17.76% to $2.78. The market value of their outstanding shares is at $32.4 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADIL

ATXS

CLDI

FBLG

HROW

ICAD

NVCT

OPRX

PDSB

TIVC

VERO

12 Health Care Stocks Moving In Thursday's Pre-Market Session

WIIM

Icad shares are trading lower after the company reported worse-than-expected Q3 revenue results.

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. The company reported quarterly sales of $4.217 million which missed the analyst consensus estimate of $4.521 million by 6.72 percent. This is a 3.54 percent increase over sales of $4.073 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

icad Q3 2024 Adj. EPS $(0.07) Beats $(0.08) Estimate, Sales $4.217M Miss $4.521M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HYZN

IBTA

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect icad to report an earnings per share (EPS) of $-0.08.
Investors in icad are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 2.94% increase in the share price the following trading session.
Here's a look at icad's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>9.0%</td>
<td>4.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731434735_0.png" alt="eps graph" />
<h3>Tracking icad's Stock Performance</h3>
Shares of icad were trading at $2.11 as of November 11. Over the last 52-week period, shares are up 64.62%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ICAD/earnings">To track all earnings releases for icad visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For icad

<a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240417" title="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240417">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240417</a>

Biotech

General

iCAD Announces The FDA 510k Review Panel Has Rated ItsProFound Detection (V4.0) For Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer, Substantially Equivalent On November 8, 2024

Icad shares are trading higher after the company reported better-than-expected Q2 revenue results

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. The company reported quarterly sales of $5.00 million which beat the analyst consensus estimate of $4.42 million by 13.06 percent. This is a 14.75 percent decrease over sales of $5.87 million the same period last year.

icad Q2 2024 GAAP EPS $(0.07), Inline, Sales $5.00M Beat $4.42M Estimate

iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategic agreement with <a href="https://www.globenewswire.com/Tracker?data=jz_5bbVlVgr_KeIBZzBtwJpyyXmLx0ZWLz2yQEtGonvNiCFICN9K_F30xFyl_wvNzq4DKkqfJ_Ste5g6b3SKYw==">Windson</a>g Radiology Group, one of US Radiology Specialists, Inc.'s national network of premier providers of diagnostic imaging services located in Western New York. This relationship aims to implement iCAD's ProFound AI Breast Health at Windsong Radiology center locations.

iCAD And Windsong Radiology Ink Strategic Commercial Agreement To Implement AI-Powered Mammography

Events

iCAD to Highlight Research On Potential Of Its AI Algorithm In Breast Cancer Risk Assessment At SIIM 2024

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 87.0% to $0.4 during Monday's after-market session. The company's market cap stands at $6.2 million. </li>
<li>MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) stock increased by 25.94% to $23.35. The market value of their outstanding shares is at $3.5 billion. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares increased by 12.49% to $0.19. The market value of their outstanding shares is at $10.4 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock moved upwards by 11.91% to $0.23. The market value of their outstanding shares is at $2.9 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares moved upwards by 10.75% to $1.75. The market value of their outstanding shares is at $46.4 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares moved upwards by 9.3% to $0.46. The market value of their outstanding shares is at $35.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock decreased by 24.4% to $1.21 during Monday's after-market session. The company's market cap stands at $49.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares decreased by 14.04% to $0.84. The company's market cap stands at $14.7 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock decreased by 12.99% to $3.62. The company's market cap stands at $2.1 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares decreased by 9.46% to $1.82. The market value of their outstanding shares is at $15.8 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares declined by 8.86% to $0.17. The company's market cap stands at $3.7 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock decreased by 8.59% to $1.81. The company's market cap stands at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

DHAI

Kintara Therapeutics, Inc. - Common Stock

KTRA

LUCY

MBIO

Morgan Stanley Capital Protected Notes for S&P 500 Index

ONCO

RNLX

SCNI

STSS

WORX

12 Health Care Stocks Moving In Monday's After-Market Session

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 58.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $4.95 million which beat the analyst consensus estimate of $4.44 million by 11.58 percent. This is a 14.31 percent increase over sales of $4.33 million the same period last year.

icad Q1 Adj $(0.05) Beats $(0.06) Estimate, Sales $4.95M Beat $4.44M Estimate

iCAD And Densitas Partner To Enhance Precision Breast Health With Leading AI Solutions

iCAD's ProFound AI Suite Uncovers Hidden Heart Disease Risk According To New Data Presented At ACC Meeting

iCad shares are trading higher after the company announced a collaboration with Rad-AID to introduce mammography AI-based decision support in LMICs.

iCAD Partners With RAD-AID To Advance Breast Cancer Detection Using AI In Underserved Regions

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported its Q4 earnings results on Tuesday, March 12, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
icad beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05.
Revenue was down $1.75 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.03 which was followed by a 7.000000000000001% drop in the share price the next day.
Here's a look at icad's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.08</td>
<td>-0.11</td>
<td>-0.11</td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.07</td>
<td>-0.14</td>
<td>-0.12</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>6.27M</td>
<td>5.80M</td>
<td>6.21M</td>
<td>6.68M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>4.07M</td>
<td>5.87M</td>
<td>5.78M</td>
<td>6.49M</td>
</tr>
</tbody>
</table>

To track all earnings releases for icad <a href="https://www.benzinga.com/quote/ICAD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

icad: Q4 Earnings Insights

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $4.741 million which beat the analyst consensus estimate of $4.300 million by 10.26 percent. This is a 26.94 percent decrease over sales of $6.489 million the same period last year.

icad Q4 2023 Adj EPS $(0.02) Beats $(0.05) Estimate, Sales $4.741M Beat $4.300M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is likely to report earnings for its fourth quarter.
&bull; MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $530.30 million.
&bull; BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) is likely to report quarterly loss at $0.91 per share on revenue of $710 thousand.
&bull; Enfusion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $45.27 million.
&bull; Tupperware Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) is estimated to report earnings for its second quarter.
&bull; Kanzhun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $214.08 million.
&bull; Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) is projected to report quarterly loss at $0.22 per share on revenue of $222.43 million.
&bull; FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $34.53 million.
&bull; Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) is projected to report quarterly earnings at $1.43 per share on revenue of $23.64 billion.
&bull; On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $510.19 million.
&bull; Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is projected to report quarterly earnings at $0.51 per share on revenue of $16.09 million.
&bull; Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $-250 thousand.
&bull; Kohl&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is estimated to report quarterly earnings at $1.28 per share on revenue of $5.70 billion.
&bull; PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWFL#NASDAQ">PWFL</a>) is likely to report quarterly loss at $0.10 per share on revenue of $34.34 million.
&bull; Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $197.93 million.
&bull; IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $476.18 million.
&bull; Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $123.96 million.
&bull; Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.24 million.
&bull; Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) is expected to report quarterly loss at $0.10 per share on revenue of $201.84 million.
&bull; Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) is estimated to report earnings for its fourth quarter.
&bull; Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $245.27 million.
&bull; ATRenew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NYSE">RERE</a>) is projected to report earnings for its fourth quarter.
&bull; Core Molding Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMT#AMEX">CMT</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $70.75 million.
&bull; Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) is projected to report quarterly earnings at $0.41 per share on revenue of $1.11 billion.
&bull; Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is projected to report quarterly loss at $0.13 per share on revenue of $48.40 million.
<h3>Companies Reporting After The Bell</h3>
&bull; ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $6.53 million.
&bull; Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $172.68 million.
&bull; MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $13.09 million.
&bull; Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $111.13 million.
&bull; Performant Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFMT#NASDAQ">PFMT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $31.59 million.
&bull; Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is expected to report quarterly earnings at $0.98 per share on revenue of $592.58 million.
&bull; Arq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQ#NASDAQ">ARQ</a>) is likely to report quarterly loss at $0.08 per share on revenue of $27.00 million.
&bull; Rackspace Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) is projected to report quarterly loss at $0.04 per share on revenue of $714.72 million.
&bull; Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $45.74 million.
&bull; Intl General Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGIC#NASDAQ">IGIC</a>) is likely to report earnings for its fourth quarter.
&bull; Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) is projected to report quarterly loss at $0.15 per share on revenue of $13.48 million.
&bull; Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) is projected to report quarterly loss at $0.27 per share on revenue of $1.60 million.
&bull; Surgepays (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $33.52 million.
&bull; Maiden Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHLD#NASDAQ">MHLD</a>) is likely to report earnings for its fourth quarter.
&bull; SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) is likely to report earnings for its fourth quarter.
&bull; Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) is projected to report quarterly loss at $2.00 per share on revenue of $2.10 million.
&bull; Doma Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOMA#NYSE">DOMA</a>) is likely to report quarterly loss at $1.30 per share on revenue of $69.42 million.
&bull; Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.07 per share on revenue of $87.63 million.
&bull; Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $8.74 million.
&bull; Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is projected to report quarterly loss at $0.13 per share on revenue of $29.34 million.
&bull; Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $4.43 million.
&bull; Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) is expected to report quarterly loss at $0.16 per share on revenue of $30.97 million.
&bull; AdTheorent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTH#NASDAQ">ADTH</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $56.20 million.
&bull; Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) is likely to report quarterly loss at $0.03 per share on revenue of $30.00 million.
&bull; Oportun Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $262.30 million.
&bull; icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is likely to report quarterly loss at $0.05 per share on revenue of $4.30 million.
&bull; Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) is expected to report quarterly loss at $0.18 per share on revenue of $145.56 million.
&bull; Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $73.07 million.
&bull; Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) is likely to report quarterly loss at $1.38 per share on revenue of $1.06 million.
&bull; Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is projected to report quarterly loss at $0.03 per share on revenue of $13.60 million.
&bull; loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $236.76 million.
&bull; CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is estimated to report quarterly loss at $0.29 per share on revenue of $58.40 million.
&bull; Synchronoss Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) is likely to report quarterly loss at $0.10 per share on revenue of $42.84 million.
&bull; Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $480.25 million.
&bull; Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $226.02 million.
&bull; Eastern Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EML#NASDAQ">EML</a>) is likely to report earnings for its fourth quarter.
&bull; BRT Apartments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRT#NYSE">BRT</a>) is estimated to report earnings for its fourth quarter.
&bull; Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is expected to report quarterly loss at $0.06 per share on revenue of $87.21 million.
&bull; Aware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWRE#NASDAQ">AWRE</a>) is estimated to report earnings for its fourth quarter.
&bull; Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is likely to report quarterly loss at $0.11 per share on revenue of $151.50 million.
&bull; Allbirds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIRD#NASDAQ">BIRD</a>) is projected to report quarterly loss at $0.23 per share on revenue of $69.06 million.
&bull; Flotek Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTK#NYSE">FTK</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $47.25 million.
&bull; PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $9.37 million.
&bull; Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) is likely to report quarterly loss at $0.15 per share on revenue of $33.79 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ADTH

ALGS

ATER

AWRE

BIRD

BLDE

BTAI

BTMD

CLOV

CLPT

CLSD

CRMD

CSBR

CYRX

DOMA

ENFN

GHLD

HGTY

HRTX

IGIC

INVE

LCUT

MANU

MHLD

MNSO

MXCT

NATR

NOTE

NRGV

ONON

OPRT

PFMT

PHUN

PRPL

PRTH

PWFL

QFIN

QRHC

REFI

RERE

SIGA

SKIN

SNCR

SURG

SWIM

TACT

TNON

VERI

WEST

WKHS

Earnings Scheduled For March 12, 2024

iCAD (ICAD) has issued an announcement. At iCAD, Inc.'s 2024 annual stockholders' meeting, a quorum of over 19 million shares voted on key proposal...

iCAD Stockholders Elect Directors, Approve Incentive Plan

In a report released today, Per Ostlund from Craig-Hallum maintained a Buy rating on iCAD (ICAD – Research Report). The company's shares closed yes...

Craig-Hallum Sticks to Their Buy Rating for iCAD (ICAD)

iCAD Non-GAAP EPS of -$0.07 in-line, revenue of $5M beats by $0.57M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
icad (NASDAQ:<a href="https://investorplace.com/stock-quotes/icad-stock-quote/">ICAD</a>) just reported results for the second quarter of 2024.<ul><li>icad reported earnings per share of -7 cents. This met the analyst estimate for EPS of -7 cents.</li><li>The company reported revenue of $5.03 million.</li><li>This was 13.78% better than the analyst estimate for revenue of $4.42 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/icad-stock-earnings-icad-for-q2-of-2024/">ICAD Stock Earnings: icad Meets EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ICAD Stock Earnings: icad Meets EPS, Beats Revenue for Q2 2024

Comments

icad

Notizie

Ultime notizie per icad (NASDAQ:ICAD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO